This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reubi, J.-C. Articles by Kvols, L. Search for Related Content PubMed PubMed Citation Articles by Reubi, J.-C. Articles by Kvols, L.

Somatostatin Receptors in Human Renal Cell Carcinomas

Sandoz Research Institute Berne Ltd., 3001 Berne, Switzerland [J-C. R.], and Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905 [L. K.]

The presence of somatostatin receptors was evaluated in samples of 39 surgically removed human renal cell carcinomas with receptor autoradiography on tumor sections by using iodinated [Tyr³]octreotide as the radioligand. All types, grades and stages of tumors were represented. Twenty-eight of 39 renal cell carcinomas (72%) were shown to be somatostatin receptor positive. The receptors were saturable, of high affinity (K_D = 0.8 nM), and were specific for somatostatin and bioactive somatostatin analogues. No evident correlations were found between the status of somatostatin receptors in the tumor and the age or sex of the patients, the histopathological type or grade of the tumor, or the tumornode-metastasis stage of the disease. However, numerous cases considered to be of poor prognosis were somatostatin receptor positive. No functional correlates for these receptors have been established, although the presence of somatostatin receptors in human kidneys and somatostatin effects on renal tubular functions in normal human volunteers have been reported. In a patient scanned in vivo for islet cell carcinomas with an ¹²³I-labeled somatostatin analogue, bilateral renal cell carcinomas were also visualized; multiple bilateral renal cell carcinomas were identified on the 1- and 4-h images taken after injection of ¹²³I-labeled somatostatin analogue. In conclusion, the high incidence of somatostatin receptors in renal cell carcinomas may have diagnostic value when performing in vivo imaging of somatostatin receptors and it may have potential therapeutic implications.

¹ To whom requests for reprints should be addressed, at the Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, 3010 Berne, Switzerland.

Received 5/29/92. Accepted 8/25/92.

This article has been cited by other articles:

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				D. A. Balster, M. S. O'Dorisio, M. A. Summers, and M. A. Turman Segmental expression of somatostatin receptor subtypes sst1 and sst2 in tubules and glomeruli of human kidney Am J Physiol Renal Physiol, March 1, 2001; 280(3): F457 - F465. [Abstract] [Full Text] [PDF]

				A. Plonowski, A. V. Schally, A. Nagy, H. Kiaris, F. Hebert, and G. Halmos Inhibition of Metastatic Renal Cell Carcinomas Expressing Somatostatin Receptors by a Targeted Cytotoxic Analogue of Somatostatin AN-238 Cancer Res., June 1, 2000; 60(11): 2996 - 3001. [Abstract] [Full Text] [PDF]

				M. A. Turman and C. A. Apple Human proximal tubular epithelial cells express somatostatin: regulation by growth factors and cAMP Am J Physiol Renal Physiol, June 1, 1998; 274(6): F1095 - F1101. [Abstract] [Full Text] [PDF]

				A. Jungwirth, A. V. Schally, J. Pinski, K. Groot, P. Armatis, and G. Halmos Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma PNAS, May 27, 1997; 94(11): 5810 - 5813. [Abstract] [Full Text] [PDF]